市場調查報告書

自行注射器的全球市場:成長,趨勢,及預測

Self-injection Device Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921255
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
自行注射器的全球市場:成長,趨勢,及預測 Self-injection Device Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 112 Pages
簡介

自行注射器,是讓患者自己注射藥物的注射器或穿戴式設備。為了定期性注射不用去診療所和醫院,帶給患者和健康護理系統雙方經濟利益,成為自行注射器市場主要成長推動要素之一。還有類風濕性關節炎和癌症等的慢性自體免疫疾病的盛行率增加也是該市場的成長要素。還有佔該市場大幅佔有率的筆型注射器預期進一步擴大。但,由於法規當局認證的嚴格法規,及新興國家對自行注射器的認識缺乏,抑制該市場的成長。

本報告提供全球自行注射器市場的相關調查,市場機會和趨勢,成長及阻礙因素,各產品、使用法、用途、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 比體檢都成本效益高
    • 慢性疾病及疾病盛行率的增加
  • 阻礙市場要素
    • 核準的嚴格法規
    • 新興國家中認識和指導的熟練者不足
  • 波特的五力分析

第5章 市場區隔

  • 各產品
    • 筆型注射器
    • 自動注射器
    • 穿戴式注射器
    • 無針注射器
  • 各使用法
    • 拋棄式
    • 可重複使用
  • 各用途
    • 癌症
    • 自體免疫疾病
    • 荷爾蒙障礙
    • 疼痛管理
    • 代謝性疾病
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Becton, Dickinson and Company
    • Gerresheimer AG
    • Insulet Corporation
    • Ypsomed AG
    • Antares Pharma Inc
    • West Pharmaceutical Services
    • Consort Medical plc
    • Sensile Medical AG
    • Owen Mumford Ltd.
    • SHL Group Auto

第7章 市場機會及今後趨勢

目錄
Product Code: 67100

Market Overview

Self-Injection devices allow patients with chronic diseases to gain control of their treatment schedule and their treatment setting, thus allowing greater independence and freedom in their social, domestic and professional lives. Self-injection may also offer psychological benefits over administration by healthcare professionals, including improved self-esteem. Removing the need to attend a clinic or hospital for regular injections also brings economic benefits to both the patient and the healthcare system. This economic benefit has been the major growth driving factor for this market. Increasing the prevalence of chronic autoimmune diseases like rheumatoid arthritis and cancer has also helped the growth as self-injections have applications in recovery from these illnesses.

However, stringent regulations for approval from regulatory authorities and lack of awareness of such devices in developing and underdeveloped economies have been restraining the growth of this market.

Scope of the Report

Self-Injection Devices are injections or wearable devices that can be used by the patient in-home setting to administer the medication himself. The market is segmented by product usage, application, and geography.

Key Market Trends

Pen Injectors are expected to cover a larger market share

Pen injectors are used for the subcutaneous delivery of biopharmaceuticals. Although they are also administered by professionals, these are primarily used for self-administration by the patient. First developed to replace vials and syringes for the treatment of diabetes with insulin, such injection devices have been an important part of the drug-delivery devices for a long time.

According to the 2018 World Health Organization report, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. This has attributed to the rise in the global prevalence of diabetes from 4.7% in 1980 to 8.5% in 2014. Moreover, diabetes prevalence has been rising more rapidly in the middle- and low-income countries. In 2016, an estimated 1.6 million deaths were directly caused by diabetes. Hence, the worldwide increase in diabetes and the growing pressure on health care costs that pushes toward patient self-injection means that their importance is expected to grow further in the future.

North America dominates the market

According to the Center for Disease Control and Prevention (CDC), in 2016, there were an estimated 15.5 million cancer survivors in the United States and this number is expected to increase to 20.3 million by 2026. According to an article by Ji Lin et al. published in Population Health Metrics Journal 2018, the projected number and percent of adults with diagnosed diabetes would increase from 22.3 million (9.1%) in 2014 to 39.7 million (13.9%) in 2030, and to 60.6 million (17.9%) in 2060. Also, the number of people with diabetes aged 65 years or older expected to increase from 9.2 million in 2014 to 21.0 million in 2030, and to 35.2 million in 2060. Hence, with the increasing prevalence of chronic diseases, the demand for self-injection devices, which are used for treatment or recovery from such diseases, is expected to increase.

Competitive Landscape

The majority of the key player involved in research and manufacturing of self-injection devices are established in developed countries. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to rising awareness.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 More Cost Effective than a Clinical Visit
    • 4.2.2 Increasing Prevalence of Chronic Disease and illnesses
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations for Approval
    • 4.3.2 Lack awareness and Instruction Experts in underdeveloped economies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Pen Injectors
    • 5.1.2 Autoinjectors
    • 5.1.3 Wearable Injectors
    • 5.1.4 Needle-Free Injectors
  • 5.2 By Usage
    • 5.2.1 Disposable
    • 5.2.2 Reusable
  • 5.3 By Application
    • 5.3.1 Cancer
    • 5.3.2 Auto Immune Diseases
    • 5.3.3 Hormonal Disorders
    • 5.3.4 Pain Management
    • 5.3.5 Metabolic Diseases
    • 5.3.6 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Gerresheimer AG
    • 6.1.3 Insulet Corporation
    • 6.1.4 Ypsomed AG
    • 6.1.5 Antares Pharma Inc
    • 6.1.6 West Pharmaceutical Services
    • 6.1.7 Consort Medical plc
    • 6.1.8 Sensile Medical AG
    • 6.1.9 Owen Mumford Ltd.
    • 6.1.10 SHL Group Auto

7 MARKET OPPORTUNITIES AND FUTURE TRENDS